Developer docs
API playgroundTry for free, no card

Search company profiles

YourChoice Therapeutics

Full company profile

uuid0000hu2

Namestring
YourChoice Therapeutics
Legal namestring
Your Choice Therapeutics
Company typeenum
Private
Founded yearint
2021
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBerkeley, United States
HQ citystring
Berkeley
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
non-hormonal contraception, male contraceptive pill, retinoic acid antagonist, clinical-stage biotech, oral contraceptive drug
Industry2 codes
PRIMARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYBPADAIAD
Sexual & Reproductive Health & Family Planning (SRH/FP) Programs
Product category
Male Contraceptive Pharmaceuticals
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical product revenue
TypeOne Time License
Description

Once YCT-529 receives regulatory approval (FDA and international equivalents), the company plans to commercialize the male contraceptive pill through partnership with larger pharmaceutical companies. Revenue will come from product sales following successful clinical trials and regulatory approval.

yourchoicetx.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

YourChoice Therapeutics is developing YCT-529, an investigational oral, non-hormonal male contraceptive pill designed to be taken daily. YCT-529 selectively blocks retinoic acid receptor-alpha (RAR-alpha) to temporarily halt sperm production while preserving testosterone, libido, and other reproductive hormones, with preclinical evidence of reversibility after discontinuation. The product is currently in Phase 2 clinical trials and is not yet approved by any regulatory authority.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • No serious adverse events reported in Phase 1a trial with 16 healthy male volunteers
+3 more records
Product overview1 text field

YourChoice Therapeutics is developing a single core product, YCT-529, an oral non-hormonal male contraceptive pill. The company is a San Francisco Bay Area biotech that licensed the technology from the University of Minnesota in 2021. YCT-529 is currently in Phase 2 clinical trials and works by selectively blocking retinoic acid receptor-alpha (RAR-alpha), a receptor essential for sperm production. The product is designed to be daily-use, reversible, and hormone-free, addressing the unmet need for male contraceptive options beyond condoms or vasectomy.

Product and service1 record
1YCT-529
CategoryMale Contraceptive Pharmaceuticals
Description

Investigational oral, non-hormonal male contraceptive pill that selectively blocks retinoic acid receptor-alpha (RAR-alpha) to temporarily halt sperm production while preserving testosterone, libido, and other reproductive hormones; preclinical data indicate reversibility after discontinuation. The product is currently in Phase 2 clinical trials and is intended for adult men seeking a reversible contraceptive option beyond condoms or vasectomy.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

YourChoice Therapeutics licensed the YCT-529 technology from the University of Minnesota in 2021. Researchers at the university developed the non-hormonal male birth control pill after a decade of research targeting the retinoic acid pathway needed for sperm production. The company is now sponsoring the drug's clinical trials.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Quotient Sciences conducted the Phase 1 clinical trial of YCT-529 at their Phase 1 unit in Nottingham, UK. The trial involved 16 healthy vasectomized men aged 32-59 years to establish safety and pharmacokinetics of the non-hormonal male contraceptive pill.

3Contracealine
Strategic tierMinorTypeOthers
Description

Contracealine is mentioned alongside YourChoice Therapeutics as advancing male contraceptive candidates in the development pipeline. YCT-529 is identified as a leading candidate in clinical development alongside NES/T and ADAM. No formal partnership relationship indicated.

ghtcoalition.org
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage company developing a long-acting, non-hormonal male contraceptive (ADAM, a hydrogel injection into the vas deferens). Directly comparable as another developer of novel non-hormonal male contraceptive products advancing in clinical trials.

TypeEmerging player
Description

Developer of Plan A, a long-acting reversible male contraceptive targeting the vas deferens. Comparable as an emerging player in the male contraceptive space pursuing non-hormonal, reversible solutions with a different delivery mechanism than YCT-529.

TypeEmerging player
Description

Early-stage biotech developing a non-hormonal male contraceptive targeting the sperm surface protein EPPIN. Comparable as a developer of novel mechanism, non-hormonal male contraceptives working toward clinical proof-of-concept.

4Male Contraceptive Initiative
TypeOthers
Description

Non-profit advocacy and funding organization actively investing in the male contraceptive pipeline, including a grant to YourChoice Therapeutics. Comparable as a key ecosystem participant shaping the male contraceptive development landscape and funding peer companies.

TypeBroad incumbent
Description

Global women's health pharmaceutical company with a portfolio of established contraceptive products. Comparable as a broad incumbent in reproductive health pharmaceuticals and a likely potential commercialization/acquisition partner for YCT-529.

TypeBroad incumbent
Description

Major pharmaceutical company with a leading contraceptive franchise (Mirena, Yaz, etc.) and history of investing in reproductive health R&D. Comparable as a broad incumbent with contraceptive commercialization capabilities and a potential partner for male contraceptive assets.

TypeBroad incumbent
Description

Large pharmaceutical company with established contraceptive products and prior male contraceptive research investments. Comparable as a broad incumbent that has historically been active in male contraceptive research and is a potential strategic acquirer.

TypeEmerging player
Description

Clinical-stage biopharmaceutical company focused on women's reproductive health with a portfolio of contraceptive candidates. Comparable as a similarly-sized clinical-stage company developing innovative reproductive health products through partnership-driven commercialization.

TypeEmerging player
Description

Women's health pharmaceutical company developing hormonal contraceptive products. Comparable as a small-cap clinical-stage reproductive health pharmaceutical company that has navigated FDA approval and commercialization of contraceptive products.

TypeOthers
Description

International non-profit research organization developing multiple contraceptive technologies, including non-hormonal approaches. Comparable as an ecosystem participant advancing the broader male contraceptive pipeline through research and clinical development.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

YourChoice Therapeutics

Male Contraceptive Pharmaceuticalsyourchoicetx.com

YourChoice Therapeutics firmographics

Firmographics
Name
YourChoice Therapeutics
Legal name
Your Choice Therapeutics
Website
https://yourchoicetx.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

YourChoice Therapeutics industry classification

Industry
Product category
Male Contraceptive Pharmaceuticals
akta.pro industry
PRIMARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYBPADAIAD
Sexual & Reproductive Health & Family Planning (SRH/FP) Programs

Keywords

  • Non-hormonal contraception
  • Male contraceptive pill
  • Retinoic acid antagonist
  • Clinical-stage biotech
  • Oral contraceptive drug

Where YourChoice Therapeutics is headquartered

Location

Headquarters

HQ city
Berkeley
HQ country
United States
HQ region
North America

Offices2 records

Markets served

YourChoice Therapeutics business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical product revenue: Once YCT-529 receives regulatory approval (FDA and international equivalents), the company plans to commercialize the male contraceptive pill through partnership with larger pharmaceutical companies. Revenue will come from product sales following successful clinical trials and regulatory approval.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

YourChoice Therapeutics product offering

Product offering

Core offering

YourChoice Therapeutics is developing YCT-529, an investigational oral, non-hormonal male contraceptive pill designed to be taken daily. YCT-529 selectively blocks retinoic acid receptor-alpha (RAR-alpha) to temporarily halt sperm production while preserving testosterone, libido, and other reproductive hormones, with preclinical evidence of reversibility after discontinuation. The product is currently in Phase 2 clinical trials and is not yet approved by any regulatory authority.

Product overview

YourChoice Therapeutics is developing a single core product, YCT-529, an oral non-hormonal male contraceptive pill. The company is a San Francisco Bay Area biotech that licensed the technology from the University of Minnesota in 2021. YCT-529 is currently in Phase 2 clinical trials and works by selectively blocking retinoic acid receptor-alpha (RAR-alpha), a receptor essential for sperm production. The product is designed to be daily-use, reversible, and hormone-free, addressing the unmet need for male contraceptive options beyond condoms or vasectomy.

Differentiator

Problem solved

Functional benefit

Products and services

  • YCT-529 Investigational oral, non-hormonal male contraceptive pill that selectively blocks retinoic acid receptor-alpha (RAR-alpha) to temporarily halt sperm production while preserving testosterone, libido, and other reproductive hormones; preclinical data indicate reversibility after discontinuation. The product is currently in Phase 2 clinical trials and is intended for adult men seeking a reversible contraceptive option beyond condoms or vasectomy.

Quantifiable outcome

  • No serious adverse events reported in Phase 1a trial with 16 healthy male volunteers
  • +3 more outcomes

Companies that use YourChoice Therapeutics

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

YourChoice Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

YourChoice Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • University of MinnesotacoreStrategic or Co-development Partner · 1 January 2021YourChoice Therapeutics licensed the YCT-529 technology from the University of Minnesota in 2021. Researchers at the university developed the non-hormonal male birth control pill after a decade of research targeting the retinoic acid pathway needed for sperm production. The company is now sponsoring the drug's clinical trials.
  • Quotient SciencescoreStrategic or Co-development PartnerQuotient Sciences conducted the Phase 1 clinical trial of YCT-529 at their Phase 1 unit in Nottingham, UK. The trial involved 16 healthy vasectomized men aged 32-59 years to establish safety and pharmacokinetics of the non-hormonal male contraceptive pill.
  • ContracealineminorOthersContracealine is mentioned alongside YourChoice Therapeutics as advancing male contraceptive candidates in the development pipeline. YCT-529 is identified as a leading candidate in clinical development alongside NES/T and ADAM. No formal partnership relationship indicated.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

YourChoice Therapeutics competitors and assessment

Company assessment

Direct peers

  • Contraline: Clinical-stage company developing a long-acting, non-hormonal male contraceptive (ADAM, a hydrogel injection into the vas deferens). Directly comparable as another developer of novel non-hormonal male contraceptive products advancing in clinical trials.

Emerging players

  • NEXT Life Sciences: Developer of Plan A, a long-acting reversible male contraceptive targeting the vas deferens. Comparable as an emerging player in the male contraceptive space pursuing non-hormonal, reversible solutions with a different delivery mechanism than YCT-529.
  • Eppin Pharma: Early-stage biotech developing a non-hormonal male contraceptive targeting the sperm surface protein EPPIN. Comparable as a developer of novel mechanism, non-hormonal male contraceptives working toward clinical proof-of-concept.
  • Dare Bioscience: Clinical-stage biopharmaceutical company focused on women's reproductive health with a portfolio of contraceptive candidates. Comparable as a similarly-sized clinical-stage company developing innovative reproductive health products through partnership-driven commercialization.
  • Agile Therapeutics: Women's health pharmaceutical company developing hormonal contraceptive products. Comparable as a small-cap clinical-stage reproductive health pharmaceutical company that has navigated FDA approval and commercialization of contraceptive products.

Others

  • Male Contraceptive Initiative: Non-profit advocacy and funding organization actively investing in the male contraceptive pipeline, including a grant to YourChoice Therapeutics. Comparable as a key ecosystem participant shaping the male contraceptive development landscape and funding peer companies.
  • Population Council: International non-profit research organization developing multiple contraceptive technologies, including non-hormonal approaches. Comparable as an ecosystem participant advancing the broader male contraceptive pipeline through research and clinical development.

Broad incumbents

  • Organon & Co. Global women's health pharmaceutical company with a portfolio of established contraceptive products. Comparable as a broad incumbent in reproductive health pharmaceuticals and a likely potential commercialization/acquisition partner for YCT-529.
  • Bayer (Pharmaceuticals): Major pharmaceutical company with a leading contraceptive franchise (Mirena, Yaz, etc.) and history of investing in reproductive health R&D. Comparable as a broad incumbent with contraceptive commercialization capabilities and a potential partner for male contraceptive assets.
  • Pfizer: Large pharmaceutical company with established contraceptive products and prior male contraceptive research investments. Comparable as a broad incumbent that has historically been active in male contraceptive research and is a potential strategic acquirer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

YourChoice Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

YourChoice Therapeutics leadership team

Management profile

Number of profiles

Profiles2 records

YourChoice Therapeutics funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

YourChoice Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about YourChoice Therapeutics

What does YourChoice Therapeutics do?

YourChoice Therapeutics is developing YCT-529, an investigational oral, non-hormonal male contraceptive pill designed to be taken daily. YCT-529 selectively blocks retinoic acid receptor-alpha (RAR-alpha) to temporarily halt sperm production while preserving testosterone, libido, and other reproductive hormones, with preclinical evidence of reversibility after discontinuation. The product is currently in Phase 2 clinical trials and is not yet approved by any regulatory authority.

Is YourChoice Therapeutics a public or private company?

YourChoice Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was YourChoice Therapeutics founded?

YourChoice Therapeutics was founded in 2021. It employs 1 to 10 people.

Where is YourChoice Therapeutics based?

YourChoice Therapeutics is headquartered in Berkeley, United States, in the North America region.

How does YourChoice Therapeutics make money?

One revenue line is on record: pharmaceutical product revenue.

Who are YourChoice Therapeutics's main competitors?

Contraline is listed as a direct peer. Emerging players are NEXT Life Sciences, Eppin Pharma, Dare Bioscience and Agile Therapeutics. Others are Male Contraceptive Initiative and Population Council. Broad incumbents are Organon & Co., Bayer (Pharmaceuticals) and Pfizer.

Does YourChoice Therapeutics have an API?

No public API is recorded for YourChoice Therapeutics.

What industry is YourChoice Therapeutics in?

YourChoice Therapeutics's product category is Male Contraceptive Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health), with a secondary code of BPADAIAD, Sexual & Reproductive Health & Family Planning (SRH/FP) Programs.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GhtcoalitionWhy investment in male contraceptive innovation mattersIn an article published around Father's Day, GHTC advocates for increased investment in male contraceptive research, highlighting that nearly 121 million unintended pregnancies occur globally each year and that women bear a disproportionate burden of pregnancy prevention due to limited male options beyond condoms and vasectomy. The article profiles several male contraceptive products in development, including Contraline's hormonal gel NES/T, Contraline's nonhormonal ADAM injectable device, and YourChoice Therapeutics' YCT529 daily pill, arguing these innovations could rebalance family planning responsibility and advance reproductive autonomy. The author contends that expanded investment in male contraceptive innovation is essential as reproductive health protections face increasing constraints worldwide.Spherical InsightsBreakthrough takes big step toward safe, reversible male contraceptionResearchers at Cornell University demonstrated in a six-year mouse study that the molecule JQ1 can temporarily block sperm production by interrupting meiosis, the cell-division process responsible for creating reproductive cells, without causing permanent fertility loss; normal sperm production and fertility returned within six weeks of stopping treatment. Published in the Proceedings of the National Academy of Sciences, the breakthrough is considered one of the most significant advances toward a safe, reversible, non-hormonal male contraceptive and could enable future products such as quarterly injections or skin patches. Growing investments from the Bill & Melinda Gates Foundation and increasing commercial activity by companies including Contraline, YourChoice Therapeutics, and NEXT Life Sciences are accelerating the path toward human applications and broader male birth-control options.BloombergThe Future of Male Birth Control Could Be Pills, Gels and ImplantsYourChoice Therapeutics, a San Francisco-based biotech startup led by co-founder Akash Bakshi, is developing YCT-529, a hormone-free male birth control pill that works by blocking a vitamin-A-dependent protein essential for sperm growth. Phase 1 human clinical trials showed the pill was well tolerated, and early results from Phase 2 trials focused on safety and efficacy are reported as promising. If successful, the company could become the first to bring a hormone-free male birth control pill to market.Gadgets 360Are Men Ready To Pop The Pill? Hormone-Free Male Contraceptive Pill Moves Closer To RealityYourChoice Therapeutics has completed a Phase 1a human safety trial for YCT-529, a hormone-free male contraceptive pill, involving 16 healthy male volunteers who received single ascending doses with no serious adverse events reported and no clinically meaningful changes in testosterone, other reproductive hormones, mood, or sexual desire. The pill works by selectively blocking retinoic acid receptors in the testes to halt sperm production while preserving testosterone levels and libido, with animal studies indicating reversibility after discontinuation. The company has now moved into extended clinical trials to determine whether sperm counts fall to contraceptive levels and how quickly fertility returns after stopping the drug, though regulatory approval remains several years away.School of Public HealthBehind the scenes: Creating a hormone-free male birth control pillResearchers at the University of Minnesota have developed YCT-529, a non-hormonal male birth control pill, after a decade of research targeting the retinoic acid pathway needed for sperm production. YourChoice Therapeutics, a San Francisco Bay Area biotech company that licensed the technology from the university in 2021, is now sponsoring the drug's clinical trials, including a Phase 1 trial in New Zealand that began in September 2024 and will conclude in January 2026. If trials succeed, the drug could reach the market within five years, though researchers note that securing FDA approval and finding a larger pharmaceutical company to commercialize the drug remain significant challenges.School of Public HealthCreating a non-hormonal male birth control pillYourChoice Therapeutics is conducting a second round of clinical trials for YCT-529, a non-hormonal male birth control pill developed by researchers at the University of Minnesota. The drug works by blocking a specific protein interaction required for sperm production and has shown safety in previous trials conducted in Great Britain. If the current trial in New Zealand succeeds, the company aims to secure FDA approval and find a larger manufacturer to bring the product to market within five years.NationNew daily contraceptive for men could end era of women bearing family planning burdenA non-hormonal male contraceptive pill called YCT-529 has successfully completed its first human safety trial with no adverse side effects, marking the first clinical trial of an oral non-hormonal male contraceptive. Developed by YourChoice Therapeutics and trialled at Quotient Sciences' Phase 1 unit in Nottingham, the pill works by temporarily and reversibly stopping sperm production. The Phase 1a trial involved 16 healthy vasectomized men aged 32-59 years, with further trials planned to establish efficacy in reducing sperm production.Business Wire BlogYourChoice Therapeutics announces second Nature publicationYourChoice Therapeutics announced that Communications Medicine, a Nature Portfolio Journal, published the results of its first-in-human study for YCT-529, showing the hormone-free male contraceptive pill was well-tolerated. The phase 1a trial involving 16 volunteers demonstrated no adverse effects on heart rate, blood parameters, or sexual desire, reinforcing the drug's safety profile as it advances to current phase 1b/2a trials in New Zealand.ParsemusStudy highlights growing demand for male contraceptivesA study published in Andrology reveals strong global demand for male contraceptives, with 61% of surveyed men interested in trying novel options within a year of availability. Interest was particularly high in low- and middle-income countries like Nigeria and Bangladesh, while U.S. interest rose following the Supreme Court's Dobbs decision. The findings highlight an urgent need for increased investment in research and development to bring products like YourChoice Therapeutics' YCT-529 to market.GoodRxMale Birth Control Options: Which One Is Right for You?Several male birth control options are currently in various stages of clinical development, including oral pills like YCT-529 and DMAU, topical gels like NES/T, and injectable devices such as ADAM. Recent updates include the completion of a phase 1 trial for YCT-529 by YourChoice Therapeutics and positive phase 2 data for the NES/T gel showing effective sperm suppression. Other candidates like Plan A by NEXT Life Sciences and TDI-11861 remain in preclinical or early clinical phases.